Gottlieb’s comments come as the Food and Drug Administration holds its first public hearing Friday on CBD with testimony lined up from some 140 manufacturers, researchers, farmers, retailers and others.
CBD products are “flooding the market” since Congress approved the sale of CBD, or cannabidiol, derived from hemp last year, Gottlieb said in an interview on CNBC’s “Squawk Box. ” Hemp is in the marijuana family, but the CBD that comes from it doesn’t have have the psychoactive ingredient Tetrahydrocannabinol (THC) that gets users high.
“Don’t think [CBD] can’t make you high. The CBD derived from cannabis does have THC in it,” Gottlieb said, noting that CBD that is manufactured from hemp does not share the same risk.
The Consumer Healthcare Products Association is lobbying the FDA to regulate CBD similar to Vitamin C, possibly establishing guidelines like dosage levels it deems safe for over-the-counter use. But Gottlieb said regulating CBD is tricky because it’s so closely related to marijuana.